5月20日早盘，中国生物制药（01177）股价表现强劲，截至上午9时56分，该股盘中大涨5.17%。
消息面上，摩根士丹利发布研报称，对中国医药行业持乐观态度。该行指出，国内推出一系列有利政策，包括对创新的全方位支持。此外，大多数国内医药公司对美国出口的依赖低，使该行业受地缘政治和美国药品定价不确定性的影响相对较小。摩根士丹利将中国生物制药的目标价从4.6港元上调至4.9港元，并维持"增持"评级，理由是该公司领先行业增长，今年内亦有丰富催化剂。
值得注意的是，尽管股价上涨，但市场上仍出现大手卖出。数据显示，中国生物制药在上午9:40出现大手卖出，成交量为87.8万股，成交价为4.22港元，涉资370.516万港元。这表明部分投资者可能选择了获利了结，但整体市场对该股仍保持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.